Ribavirin increases early and sustained virological response rates in patients chronically infected with HCV who receive pegylated interferon-α and novel HCV protease inhibitors.
Methods
To better characterize antiviral efficacies of these upcoming therapies, Huh7 cells harbouring a subgenomic HCV replicon system were cultivated with various doses and combinations of ribavirin, interferon-α, and the protease inhibitors boceprevir and telaprevir. Antiviral efficacy parameters were estimated from HCV RNA decay, and synergistic effects of combination therapies were analysed with the Bliss independency model.
Results
Single-drug antiviral activities showed dose-dependent HCV RNA reductions in replicon cells (50% inhibitory concentration of 386.16 μM, 81.67 IU, 0.44 μM and 0.81 μM after 48 h for ribavirin, interferon-α, boceprevir and telaprevir, respectively). For the dual combination of ribavirin with either boceprevir or telaprevir, no deviation from additivity was observed, whereas the reduction of HCV RNA was synergistic for ribavirin with interferon-α (P<0.001). Triple combinations with ribavirin, interferon-α and protease inhibitors showed the most profound HCV RNA decay.
Conclusions
The beneficial in vitro antiviral effect of ribavirin with interferon-α and novel HCV protease inhibitors demonstrates that ribavirin may be required as an antiviral backbone in the near future.
References
1.
StraderD.B., WrightT., ThomasD.L., SeeffL.B.Diagnosis, management, and treatment of hepatitis C. Hepatology2004; 39: 1147–1171.
2.
FattovichG., StroffoliniT., ZagniI., DonatoF.Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology2004; 127: S35–S50.
3.
VeldtB.J., HeathcoteE.J., WedemeyerH.Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med2007; 147: 677–684.
4.
HoofnagleJ.H., SeeffL.B.Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med2006; 355: 2444–2451.
5.
MannsM.P., FosterG.R., RockstrohJ.K., ZeuzemS., ZoulimF., HoughtonM.The way forward in HCV treatment – finding the right path. Nat Rev Drug Discov2007; 6: 991–1000.
6.
PawlotskyJ.M., ChevaliezS., McHutchisonJ.G.The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology2007; 132: 1979–1998.
7.
KwoP.Y., LawitzE.J., McConeJ.Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet2010; 376: 705–716.
8.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med2009; 360: 1839–1850.
9.
PereiraA.A., JacobsonI.M.New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol2009; 6: 403–411.
10.
BainV.G., LeeS.S., PeltekianK.Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin. Aliment Pharmacol Ther2008; 28: 43–50.
11.
MaynardM., GagnieuM.C., PradatP., SouvignetC., TrepoC.Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther2008; 13: 607–611.
12.
Loustaud-RattiV., AlainS., RousseauA.Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology2008; 47: 1453–1461.
13.
SulkowskiM., ShiffmanM., AfdhalN.Hepatitis C virus treatment-related anemia is associated with higher sustained virological response rate. Gastroenterology2010; 139: 1602–1611.
14.
ReddyK.R., ShiffmanM.L., MorganT.R.Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol2007; 5: 124–129.
15.
LohmannV., KornerF., DobierzewskaA., BartenschlagerR.Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol2001; 75: 1437–1449.
16.
HofmannW.P., PoltaA., HerrmannE.Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology2007; 132: 921–930.
17.
BerenbaumM.C.What is synergy?Pharmacol Rev1989; 41: 93–141.
18.
GrecoW.R., BravoG., ParsonsJ.C.The search for synergy: a critical review from a response surface perspective. Pharmacol Rev1995; 47: 331–385.
19.
DrusanoG.L., D'ArgenioD.Z., SymondsW.Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother1998; 42: 2153–2159.
20.
LinK., KwongA.D., LinC.Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother2004; 48: 4784–4792.
21.
PrichardM.N., ShipmanC.Jr.. A three-dimensional model to analyze drug–drug interactions. Antiviral Res1990; 14: 181–205.
22.
CoelmontL., PaeshuyseJ., WindischM.P., De ClercqE., BartenschlagerR., NeytsJ.Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother2006; 50: 3444–3446.
23.
ShiffmanM.L.What future for ribavirin?Liver Int2009; 29Suppl 1: 68–73.
24.
InoueY., HommaM., MatsuzakiY.Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res2006; 34: 23–27.
25.
HommaM., MatsuzakiY., InoueY.Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol2004; 2: 337–339.
26.
PaeshuyseJ., VliegenI., CoelmontL.Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob Agents Chemother2008; 52: 3433–3437.
27.
WohnslandA., HofmannW.P., SarrazinC.Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev2007; 20: 23–38.
28.
ChungR.T., GaleM.Jr., PolyakS.J., LemonS.M., LiangT.J., HoofnagleJ.H.Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop. Hepatology2008; 47: 306–320.
29.
TanabeY., SakamotoN., EnomotoN.Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis2004; 189: 1129–1139.
30.
KatoT., DateT., MiyamotoM.Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol2005; 43: 5679–5684.
31.
LinT.I., LenzO., FanningG.In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother2009; 53: 1377–1385.
32.
FeldJ.J., HoofnagleJ.H.Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature2005; 436: 967–972.
33.
HofmannW.P., HerrmannE., SarrazinC., ZeuzemS.Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int2008; 28: 1332–1343.
34.
FeldJ.J., NandaS., HuangY.Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology2007; 46: 1548–1563.
35.
ThomasE., FeldJ.J., LiQ., HuZ., FriedM.W., LiangT.J.Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology2011; 53: 32–41.
36.
VogtM.W., HartshornK.L., FurmanP.A.Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science1987; 235: 1376–1379.
37.
Hernandez-SantiagoB.I., BassitL., GrierJ., SchinaziR.F.Anti-HCV activity and cellular pharmacology of 2′-C-methyl-cytidine alone and in combination with non-toxic concentrations of ribavirin in the HCV replicon system. Antivir Ther2007; 12Suppl 1: S28.
38.
SarrazinC., ZeuzemS.Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology2010; 138: 447–462.
39.
MathyJ.E., MaS., ComptonT., LinK.Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother2008; 52: 3267–3275.
40.
CoelmontL., KapteinS., PaeshuyseJ.Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother2009; 53: 967–976.
